Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 targeting Affibody molecules are a class of small, engineered scaffold proteins designed to selectively bind to CD276 (B7-H3), an immune checkpoint protein overexpressed in various solid tumors, including neuroblastoma, ovarian cancer, and colorectal cancer. Developed by Affibody AB in collaboration with Uppsala University, these molecules are based on a three-helix bundle domain derived from staphylococcal protein A. Due to their small size (~6-7 kDa), they offer rapid tissue penetration and blood clearance, making them highly suitable for both precision diagnostic imaging (when labeled with radionuclides like Gallium-68 or Technetium-99m) and targeted radionuclide therapy (when fused with an albumin-binding domain for half-life extension and labeled with Lutetium-177). Preclinical studies have demonstrated high specificity, affinity, and tumor-targeting properties in various cancer models.
| Indication | Highest phase | Status |
|---|---|---|
| colorectal cancer (CRC) and precursor lesions | Preclinical | Active |
| neuroblastoma | Preclinical | Active |
| neuroblastoma (MYCN-amplified / non-amplified) | Preclinical | Active |
| ovarian cancer and premalignant lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: colorectal cancer (CRC) and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B7-H3 targeting Affibody molecules.
Work on B7-H3 targeting Affibody molecules? Claim this page to correct or add information. Claim this page